Keppra is indicated as adjunctive therapy
- in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents, children and infants from 1 month of age with epilepsy.
- in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.
- in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.
| Manufacturer | GSK |
|---|---|
| Brand Name | KEPPRA |
| Dosage | USED AS PRESCRIBED |
| Dosage Form | TABLETS |
| Size | 100 |
| Active Ingredients | Levetiracetam |
| Side Effects | N/A |
| Contraindications | N/A |
Write Your Own Review